State Street’s Cerevel Therapeutics Holdings CERE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-3,109,886
Closed -$127M – 4394
2024
Q2
$127M Sell
3,109,886
-418,584
-12% -$17.4M 0.01% 1117
2024
Q1
$149M Buy
3,528,470
+676,651
+24% +$28.4M 0.01% 1056
2023
Q4
$121M Sell
2,851,819
-48,516
-2% -$1.39M 0.01% 1166
2023
Q3
$63.3M Buy
2,900,335
+132,058
+5% +$3.3M ﹤0.01% 1475
2023
Q2
$88M Sell
2,768,277
-369,309
-12% -$11.3M ﹤0.01% 1311
2023
Q1
$76.5M Sell
3,137,586
-286,634
-8% -$8.41M ﹤0.01% 1367
2022
Q4
$108M Buy
3,424,220
+704,948
+26% +$19.9M 0.01% 1114
2022
Q3
$76.8M Buy
2,719,272
+304,798
+13% +$9.08M ﹤0.01% 1295
2022
Q2
$63.8M Buy
2,414,474
+252,378
+12% +$7.17M ﹤0.01% 1465
2022
Q1
$75.7M Sell
2,162,096
-55,152
-2% -$1.61M ﹤0.01% 1492
2021
Q4
$71.9M Buy
2,217,248
+55,476
+3% +$1.96M ﹤0.01% 1551
2021
Q3
$63.8M Buy
2,161,772
+852,253
+65% +$23.9M ﹤0.01% 1623
2021
Q2
$33.6M Buy
1,309,519
+377,383
+40% +$5.4M ﹤0.01% 2138
2021
Q1
$12.8M Buy
+932,136
New +$13.6M ﹤0.01% 2620

Other funds holding CERE

State Street's CERE Position: Q3 2024 in Review

State Street sold out of Cerevel Therapeutics Holdings (CERE) in Q3 2024, closing a stake of 3,109,886 shares — an estimated $127M sold.

State Street first reported a position in CERE in Q1 2021 and held it in 14 quarters. The position peaked at $149M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • State Street reported no remaining Cerevel Therapeutics Holdings position as of Q3 2024 after selling out during the quarter.
  • State Street sold 3,109,886 Cerevel Therapeutics Holdings shares in Q3 2024, an estimated $127M.
  • State Street first reported a position in Cerevel Therapeutics Holdings in Q1 2021 and held it in 14 quarters.
  • State Street's Cerevel Therapeutics Holdings position peaked at $149M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings as of Q3 2024.

Based on State Street's 13F filing for Q3 2024, filed 14 Nov 2024.